Patents by Inventor Stephen W Kaldor

Stephen W Kaldor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF RAF KINASES
    Publication number: 20220089569
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: September 16, 2021
    Publication date: March 24, 2022
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, John TYHONAS, Eric MURPHY, Jason COX, Robert KANIA
  • TERPINOID DERIVATIVES AND USES THEREOF
    Publication number: 20220017566
    Abstract: Described herein are terpinoid derivatives as NRF2 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of inflammatory diseases.
    Type: Application
    Filed: September 23, 2019
    Publication date: January 20, 2022
    Inventors: Bohan JIN, Qing DONG, Gene HUNG, Stephen W. KALDOR
  • INHIBITORS OF RAF KINASES
    Publication number: 20210300904
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: March 25, 2021
    Publication date: September 30, 2021
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, John TYHONAS, Eric MURPHY
  • Inhibitors of RAF kinases
    Patent number: 11098031
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: August 24, 2021
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, Toufike Kanouni, John Tyhonas, Eric Murphy
  • INHIBITORS OF RAF KINASES
    Publication number: 20210246135
    Abstract: Provided herein are heteroaryl inhibitors of receptor tyrosine kinase effector (RAF), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of disease.
    Type: Application
    Filed: February 4, 2021
    Publication date: August 12, 2021
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, Lee ARNOLD
  • Inhibitors of lysine specific demethylase-1
    Patent number: 11084793
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: August 10, 2021
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Young K. Chen, Toufike Kanouni, Stephen W. Kaldor, Jeffrey Alan Stafford, James Marvin Veal
  • Substituted pyridines as TYK2 inhibitors
    Patent number: 11053219
    Abstract: Described herein are pyridine compounds of Formula (XIII) that are useful in treating a TYK2-mediated disorder.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: July 6, 2021
    Assignee: Esker Therapeutics, Inc.
    Inventors: Bohan Jin, Qing Dong, Gene Hung, Stephen W. Kaldor
  • INHIBITORS OF CYCLIN-DEPENDENT KINASES
    Publication number: 20210130340
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: November 11, 2020
    Publication date: May 6, 2021
    Inventors: Toufike KANOUNI, Lee D. ARNOLD, Stephen W. KALDOR, Eric A. MURPHY, John TYHONAS
  • INHIBITORS OF CYCLIN-DEPENDENT KINASES
    Publication number: 20210053969
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: May 2, 2019
    Publication date: February 25, 2021
    Inventors: Toufike KANOUNI, Lee ARNOLD, Stephen W. KALDOR, Eric A. MURPHY
  • Inhibitors of RAF kinases
    Patent number: 10927111
    Abstract: Provided herein are heteroaryl inhibitors of receptor tyrosine kinase effector (RAF), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of disease.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: February 23, 2021
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, Toufike Kanouni, Lee Arnold
  • Inhibitors of cyclin-dependent kinases
    Patent number: 10894788
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: January 19, 2021
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas
  • TYK2 INHIBITORS AND USES THEREOF
    Publication number: 20200354338
    Abstract: Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
    Type: Application
    Filed: July 24, 2020
    Publication date: November 12, 2020
    Inventors: Bohan JIN, Qing DONG, Gene HUNG, Stephen W. Kaldor
  • INHIBITORS OF RAF KINASES
    Publication number: 20200347052
    Abstract: Provided herein are heteroaryl inhibitors of receptor tyrosine kinase effector (RAF), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of disease.
    Type: Application
    Filed: April 30, 2020
    Publication date: November 5, 2020
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, Lee ARNOLD
  • Bromodomain inhibitors
    Patent number: 10807982
    Abstract: The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: October 20, 2020
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Michael John Bennett, Juan Manual Betancort, Amogh Boloor, Stephen W. Kaldor, Jeffrey Alan Stafford, James M. Veal
  • INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1
    Publication number: 20200231549
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: April 6, 2020
    Publication date: July 23, 2020
    Applicant: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Young K. Chen, Toufike Kanouni, Stephen W. Kaldor, Jeffrey Alan Stafford, James Marvin Veal
  • Compositions comprising an inhibitor of lysine specific demethylase-1
    Patent number: 10703739
    Abstract: Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the lysine specific demethylase-1 inhibitor 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile. Also described are pharmaceutical compositions suitable for administration to a mammal that include the lysine specific demethylase-1 inhibitor, and methods of using the lysine specific demethylase-1 inhibitor for treating diseases or conditions that are associated with lysine specific demethylase-1 activity.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: July 7, 2020
    Assignee: Calgene Quanticel Research, Inc.
    Inventors: Young K. Chen, Toufike Kanouni, Stephen W. Kaldor, Jeffrey Alan Stafford, James Marvin Veal, Paula Alessandra Tavares-Greco, Matthew Michael Kreilein
  • Inhibitors of lysine specific demethylase-1
    Patent number: 10654810
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: May 19, 2020
    Assignee: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Young K. Chen, Toufike Kanouni, Stephen W. Kaldor, Jeffrey Alan Stafford, James Marvin Veal
  • INHIBITORS OF CYCLIN-DEPENDENT KINASES
    Publication number: 20200024266
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: June 28, 2019
    Publication date: January 23, 2020
    Inventors: Toufike KANOUNI, Lee D. ARNOLD, Stephen W. KALDOR, Eric A. MURPHY, John TYHONAS
  • COMPOSITIONS COMPRISING AN INHIBITOR OF LYSINE SPECIFIC DEMETHYLASE-1
    Publication number: 20190367473
    Abstract: Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the lysine specific demethylase-1 inhibitor 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile. Also described are pharmaceutical compositions suitable for administration to a mammal that include the lysine specific demethylase-1 inhibitor, and methods of using the lysine specific demethylase-1 inhibitor for treating diseases or conditions that are associated with lysine specific demethylase-1 activity.
    Type: Application
    Filed: June 10, 2019
    Publication date: December 5, 2019
    Applicant: Celgene Quanticel Research, Inc.
    Inventors: Young K. Chen, Toufike Kanouni, Stephen W. Kaldor, Jeffrey Alan Stafford, James Marvin Veal, Paula Alessandra Tavares-Greco, Matthew Michael Kreilein
  • Bromodomain inhibitors
    Patent number: 10494371
    Abstract: The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: December 3, 2019
    Assignee: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Michael John Bennett, Juan Manuel Betancort, Amogh Boloor, Stephen W. Kaldor, Jeffrey Alan Stafford, James Marvin Veal